Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer

Patricia Harrigan Hardenbergh, Abram Recht, Smitha Valli Gollamudi, Steven E. Come, Daniel F. Hayes, Lawrence N. Shulman, Anne O'Neill, Rebecca S. Gelman, Barbara Silver, Jay R. Harris

Research output: Contribution to journalArticle

Abstract

Purpose: There is concern that breast cancer patients treated with left- sided radiation therapy (XRT) and doxorubicin (DOX) may have an increased risk of cardiac toxicity. In addition, the effect of different sequencing of XRT and chemotherapy (CT) on the likelihood of cardiotoxicity, as well as cellulitis, arm edema, or brachial plexopathy, is not well understood. We reviewed the records of patients treated on a randomized trial testing the sequencing of CT and XRT to determine if there was an increase in cardiac events or other complications in patients treated with a total dose of DOX of 180 mg/m2 and XRT, comparing patients with treatment to the left breast and the right breast, and comparing patients treated with initial CT and initial RT. Materials and Methods: From June 1984 to December 1992, 244 patients with clinical stage I or II breast cancer were randomized following conservative surgery to receive CT (4 cycles of CAMFP at 3 week intervals) either before or after XRT (45 Gy to the entire breast, followed by a boost of 16 Gy; nodal radiation therapy was optional). Two hundred thirty-one patients were evaluable for the development of cardiac toxicity. The median age at diagnosis was 45 years (range, 20-68). CT doses were: doxorubicin, 45 mg/m2 IV bolus, d 3; methotrexate, 200 mg/m2 IV, d 1 and 15; 5-fluorouracil, 500 mg/m2 IV, d 1; cyclophosphamide, 500 mg/m2 IV, d 1; prednisone 40 mg p,o., d 1-5. A cardiac event was defined as a myocardial infarction or clinical evidence of congestive heart failure. Median follow-up time was 53 months. Results: No cardiac events were observed for patients with either left- or right-sided breast cancer. The sequencing of CT and XRT had no significant effect on the risk of cardiac toxicity, cellulitis, arm edema or brachial plexopathy. Conclusions: We observed no evidence of an increased risk of cardiac toxicity from the addition of left breast tangential irradiation to DOX at a total dose of 180 mg/m2. Additional follow-up is needed to exclude possible late events. In addition, the sequencing of CT and XRT does not appear to affect the risk of cellulitis, arm edema, or brachial plexopathy.

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume45
Issue number1
DOIs
StatePublished - Aug 1 1999
Externally publishedYes

Fingerprint

sequencing
breast
toxicity
Doxorubicin
chemotherapy
radiation therapy
therapy
Radiotherapy
cancer
Breast Neoplasms
Drug Therapy
Brachial Plexus Neuropathies
edema
Cellulitis
Breast
Edema
Arm
Therapeutics
dosage
myocardial infarction

Keywords

  • Arm edema
  • Brachial plexopathy
  • Breast cancer
  • Cardiac toxicity
  • Cellulitis
  • Doxorubicin
  • Late effects
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. / Hardenbergh, Patricia Harrigan; Recht, Abram; Gollamudi, Smitha Valli; Come, Steven E.; Hayes, Daniel F.; Shulman, Lawrence N.; O'Neill, Anne; Gelman, Rebecca S.; Silver, Barbara; Harris, Jay R.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 45, No. 1, 01.08.1999, p. 69-72.

Research output: Contribution to journalArticle

Hardenbergh, Patricia Harrigan ; Recht, Abram ; Gollamudi, Smitha Valli ; Come, Steven E. ; Hayes, Daniel F. ; Shulman, Lawrence N. ; O'Neill, Anne ; Gelman, Rebecca S. ; Silver, Barbara ; Harris, Jay R. / Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. In: International Journal of Radiation Oncology, Biology, Physics. 1999 ; Vol. 45, No. 1. pp. 69-72.
@article{7d5e25a3d03b4620ba4d8f00f0c7c8c5,
title = "Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer",
abstract = "Purpose: There is concern that breast cancer patients treated with left- sided radiation therapy (XRT) and doxorubicin (DOX) may have an increased risk of cardiac toxicity. In addition, the effect of different sequencing of XRT and chemotherapy (CT) on the likelihood of cardiotoxicity, as well as cellulitis, arm edema, or brachial plexopathy, is not well understood. We reviewed the records of patients treated on a randomized trial testing the sequencing of CT and XRT to determine if there was an increase in cardiac events or other complications in patients treated with a total dose of DOX of 180 mg/m2 and XRT, comparing patients with treatment to the left breast and the right breast, and comparing patients treated with initial CT and initial RT. Materials and Methods: From June 1984 to December 1992, 244 patients with clinical stage I or II breast cancer were randomized following conservative surgery to receive CT (4 cycles of CAMFP at 3 week intervals) either before or after XRT (45 Gy to the entire breast, followed by a boost of 16 Gy; nodal radiation therapy was optional). Two hundred thirty-one patients were evaluable for the development of cardiac toxicity. The median age at diagnosis was 45 years (range, 20-68). CT doses were: doxorubicin, 45 mg/m2 IV bolus, d 3; methotrexate, 200 mg/m2 IV, d 1 and 15; 5-fluorouracil, 500 mg/m2 IV, d 1; cyclophosphamide, 500 mg/m2 IV, d 1; prednisone 40 mg p,o., d 1-5. A cardiac event was defined as a myocardial infarction or clinical evidence of congestive heart failure. Median follow-up time was 53 months. Results: No cardiac events were observed for patients with either left- or right-sided breast cancer. The sequencing of CT and XRT had no significant effect on the risk of cardiac toxicity, cellulitis, arm edema or brachial plexopathy. Conclusions: We observed no evidence of an increased risk of cardiac toxicity from the addition of left breast tangential irradiation to DOX at a total dose of 180 mg/m2. Additional follow-up is needed to exclude possible late events. In addition, the sequencing of CT and XRT does not appear to affect the risk of cellulitis, arm edema, or brachial plexopathy.",
keywords = "Arm edema, Brachial plexopathy, Breast cancer, Cardiac toxicity, Cellulitis, Doxorubicin, Late effects, Radiation therapy",
author = "Hardenbergh, {Patricia Harrigan} and Abram Recht and Gollamudi, {Smitha Valli} and Come, {Steven E.} and Hayes, {Daniel F.} and Shulman, {Lawrence N.} and Anne O'Neill and Gelman, {Rebecca S.} and Barbara Silver and Harris, {Jay R.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1016/S0360-3016(99)00127-3",
language = "English (US)",
volume = "45",
pages = "69--72",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer

AU - Hardenbergh, Patricia Harrigan

AU - Recht, Abram

AU - Gollamudi, Smitha Valli

AU - Come, Steven E.

AU - Hayes, Daniel F.

AU - Shulman, Lawrence N.

AU - O'Neill, Anne

AU - Gelman, Rebecca S.

AU - Silver, Barbara

AU - Harris, Jay R.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Purpose: There is concern that breast cancer patients treated with left- sided radiation therapy (XRT) and doxorubicin (DOX) may have an increased risk of cardiac toxicity. In addition, the effect of different sequencing of XRT and chemotherapy (CT) on the likelihood of cardiotoxicity, as well as cellulitis, arm edema, or brachial plexopathy, is not well understood. We reviewed the records of patients treated on a randomized trial testing the sequencing of CT and XRT to determine if there was an increase in cardiac events or other complications in patients treated with a total dose of DOX of 180 mg/m2 and XRT, comparing patients with treatment to the left breast and the right breast, and comparing patients treated with initial CT and initial RT. Materials and Methods: From June 1984 to December 1992, 244 patients with clinical stage I or II breast cancer were randomized following conservative surgery to receive CT (4 cycles of CAMFP at 3 week intervals) either before or after XRT (45 Gy to the entire breast, followed by a boost of 16 Gy; nodal radiation therapy was optional). Two hundred thirty-one patients were evaluable for the development of cardiac toxicity. The median age at diagnosis was 45 years (range, 20-68). CT doses were: doxorubicin, 45 mg/m2 IV bolus, d 3; methotrexate, 200 mg/m2 IV, d 1 and 15; 5-fluorouracil, 500 mg/m2 IV, d 1; cyclophosphamide, 500 mg/m2 IV, d 1; prednisone 40 mg p,o., d 1-5. A cardiac event was defined as a myocardial infarction or clinical evidence of congestive heart failure. Median follow-up time was 53 months. Results: No cardiac events were observed for patients with either left- or right-sided breast cancer. The sequencing of CT and XRT had no significant effect on the risk of cardiac toxicity, cellulitis, arm edema or brachial plexopathy. Conclusions: We observed no evidence of an increased risk of cardiac toxicity from the addition of left breast tangential irradiation to DOX at a total dose of 180 mg/m2. Additional follow-up is needed to exclude possible late events. In addition, the sequencing of CT and XRT does not appear to affect the risk of cellulitis, arm edema, or brachial plexopathy.

AB - Purpose: There is concern that breast cancer patients treated with left- sided radiation therapy (XRT) and doxorubicin (DOX) may have an increased risk of cardiac toxicity. In addition, the effect of different sequencing of XRT and chemotherapy (CT) on the likelihood of cardiotoxicity, as well as cellulitis, arm edema, or brachial plexopathy, is not well understood. We reviewed the records of patients treated on a randomized trial testing the sequencing of CT and XRT to determine if there was an increase in cardiac events or other complications in patients treated with a total dose of DOX of 180 mg/m2 and XRT, comparing patients with treatment to the left breast and the right breast, and comparing patients treated with initial CT and initial RT. Materials and Methods: From June 1984 to December 1992, 244 patients with clinical stage I or II breast cancer were randomized following conservative surgery to receive CT (4 cycles of CAMFP at 3 week intervals) either before or after XRT (45 Gy to the entire breast, followed by a boost of 16 Gy; nodal radiation therapy was optional). Two hundred thirty-one patients were evaluable for the development of cardiac toxicity. The median age at diagnosis was 45 years (range, 20-68). CT doses were: doxorubicin, 45 mg/m2 IV bolus, d 3; methotrexate, 200 mg/m2 IV, d 1 and 15; 5-fluorouracil, 500 mg/m2 IV, d 1; cyclophosphamide, 500 mg/m2 IV, d 1; prednisone 40 mg p,o., d 1-5. A cardiac event was defined as a myocardial infarction or clinical evidence of congestive heart failure. Median follow-up time was 53 months. Results: No cardiac events were observed for patients with either left- or right-sided breast cancer. The sequencing of CT and XRT had no significant effect on the risk of cardiac toxicity, cellulitis, arm edema or brachial plexopathy. Conclusions: We observed no evidence of an increased risk of cardiac toxicity from the addition of left breast tangential irradiation to DOX at a total dose of 180 mg/m2. Additional follow-up is needed to exclude possible late events. In addition, the sequencing of CT and XRT does not appear to affect the risk of cellulitis, arm edema, or brachial plexopathy.

KW - Arm edema

KW - Brachial plexopathy

KW - Breast cancer

KW - Cardiac toxicity

KW - Cellulitis

KW - Doxorubicin

KW - Late effects

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0032807557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032807557&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(99)00127-3

DO - 10.1016/S0360-3016(99)00127-3

M3 - Article

C2 - 10477008

AN - SCOPUS:0032807557

VL - 45

SP - 69

EP - 72

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -